Anti-PD-1 antibodies and methods of use thereof

US10323091B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• Memorial Sloan Kettering Cancer Center · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Marc van Dijk · Bosch en Duin, NL
• Nicholas Stuart Wilson · Melbourne, AU
• Cornelia Anne Mundt · Lörrach, DE
• Gerd Ritter · New York, US
• Jedd D. Wolchok · New York, US
• Taha Merghoub · New York, US
• Roberta Zappasodi · New York, US
• Rikke Bæk Holmgaard · New York, US
• David Schaer · Mamaroneck, US
• David Adam Savitsky · Boxford, US

Key dates

• Filing date: Sep 1, 2016
• Grant date: Jun 18, 2019
• Expiry date: Oct 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.